1. CML 25 Years Later - Poised for Another Breakthrough?
- Author
-
Abruzzese E
- Subjects
- Humans, Fusion Proteins, bcr-abl antagonists & inhibitors, Fusion Proteins, bcr-abl genetics, History, 20th Century, History, 21st Century, Clinical Trials, Phase III as Topic, Imatinib Mesylate administration & dosage, Imatinib Mesylate adverse effects, Niacinamide administration & dosage, Niacinamide adverse effects, Niacinamide analogs & derivatives, Pyrazoles administration & dosage, Pyrazoles adverse effects, Randomized Controlled Trials as Topic, Treatment Outcome, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Agents history, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive history, Tyrosine Kinase Inhibitors administration & dosage, Tyrosine Kinase Inhibitors adverse effects, Tyrosine Kinase Inhibitors history
- Published
- 2024
- Full Text
- View/download PDF